Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00160329 | Breast | Precancer | viral process | 58/1080 | 415/18723 | 3.42e-10 | 3.16e-08 | 58 |
GO:00190589 | Breast | Precancer | viral life cycle | 47/1080 | 317/18723 | 2.42e-09 | 1.99e-07 | 47 |
GO:00444039 | Breast | Precancer | biological process involved in symbiotic interaction | 42/1080 | 290/18723 | 3.40e-08 | 2.11e-06 | 42 |
GO:00521269 | Breast | Precancer | movement in host environment | 29/1080 | 175/18723 | 2.59e-07 | 1.28e-05 | 29 |
GO:00517019 | Breast | Precancer | biological process involved in interaction with host | 31/1080 | 203/18723 | 6.52e-07 | 2.71e-05 | 31 |
GO:00444099 | Breast | Precancer | entry into host | 25/1080 | 151/18723 | 1.74e-06 | 6.19e-05 | 25 |
GO:00467189 | Breast | Precancer | viral entry into host cell | 24/1080 | 144/18723 | 2.46e-06 | 8.35e-05 | 24 |
GO:001603214 | Breast | IDC | viral process | 75/1434 | 415/18723 | 1.98e-12 | 4.02e-10 | 75 |
GO:001905814 | Breast | IDC | viral life cycle | 61/1434 | 317/18723 | 1.61e-11 | 2.77e-09 | 61 |
GO:004440314 | Breast | IDC | biological process involved in symbiotic interaction | 52/1434 | 290/18723 | 6.55e-09 | 5.03e-07 | 52 |
GO:005212614 | Breast | IDC | movement in host environment | 32/1434 | 175/18723 | 3.33e-06 | 1.22e-04 | 32 |
GO:005170114 | Breast | IDC | biological process involved in interaction with host | 35/1434 | 203/18723 | 4.72e-06 | 1.63e-04 | 35 |
GO:004440914 | Breast | IDC | entry into host | 28/1434 | 151/18723 | 1.02e-05 | 2.82e-04 | 28 |
GO:004671814 | Breast | IDC | viral entry into host cell | 27/1434 | 144/18723 | 1.18e-05 | 3.14e-04 | 27 |
GO:001603224 | Breast | DCIS | viral process | 73/1390 | 415/18723 | 3.40e-12 | 6.88e-10 | 73 |
GO:001905824 | Breast | DCIS | viral life cycle | 59/1390 | 317/18723 | 4.05e-11 | 5.74e-09 | 59 |
GO:004440323 | Breast | DCIS | biological process involved in symbiotic interaction | 49/1390 | 290/18723 | 4.70e-08 | 2.89e-06 | 49 |
GO:005212624 | Breast | DCIS | movement in host environment | 31/1390 | 175/18723 | 4.93e-06 | 1.45e-04 | 31 |
GO:005170124 | Breast | DCIS | biological process involved in interaction with host | 34/1390 | 203/18723 | 6.30e-06 | 1.78e-04 | 34 |
GO:004440924 | Breast | DCIS | entry into host | 27/1390 | 151/18723 | 1.65e-05 | 4.00e-04 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANPEP | SNV | Missense_Mutation | rs141631662 | c.1088N>A | p.Arg363Gln | p.R363Q | P15144 | protein_coding | tolerated(0.13) | possibly_damaging(0.844) | TCGA-A2-A0CV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ANPEP | SNV | Missense_Mutation | | c.256N>T | p.Arg86Trp | p.R86W | P15144 | protein_coding | deleterious(0.01) | possibly_damaging(0.773) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ANPEP | SNV | Missense_Mutation | rs766949181 | c.67G>A | p.Val23Met | p.V23M | P15144 | protein_coding | deleterious(0.04) | benign(0.441) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANPEP | SNV | Missense_Mutation | | c.422N>A | p.Gly141Asp | p.G141D | P15144 | protein_coding | tolerated(0.21) | possibly_damaging(0.606) | TCGA-BH-A0BC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
ANPEP | SNV | Missense_Mutation | rs376373199 | c.2831C>T | p.Thr944Met | p.T944M | P15144 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD |
ANPEP | SNV | Missense_Mutation | | c.1928N>C | p.Gln643Pro | p.Q643P | P15144 | protein_coding | deleterious(0.03) | possibly_damaging(0.625) | TCGA-D8-A27M-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | methotrexate+5 | SD |
ANPEP | SNV | Missense_Mutation | | c.881N>T | p.Ala294Val | p.A294V | P15144 | protein_coding | tolerated(0.35) | benign(0.026) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
ANPEP | insertion | In_Frame_Ins | novel | c.2569_2570insGTG | p.Gln857delinsArgGlu | p.Q857delinsRE | P15144 | protein_coding | | | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
ANPEP | insertion | In_Frame_Ins | novel | c.2568_2569insGGGCACTCCATTCTTCTCCCG | p.Lys856_Gln857insGlyHisSerIleLeuLeuPro | p.K856_Q857insGHSILLP | P15144 | protein_coding | | | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
ANPEP | deletion | In_Frame_Del | novel | c.2300_2302delAGT | p.Glu767_Cys768delinsGly | p.E767_C768delinsG | P15144 | protein_coding | | | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
290 | ANPEP | NEUTRAL ZINC METALLOPEPTIDASE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, PROTEASE, ENZYME | | RECOMBINANT ERYTHROPOIETIN | | 15957544 |
290 | ANPEP | NEUTRAL ZINC METALLOPEPTIDASE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | CHEMBL2103847 | TOSEDOSTAT | |
290 | ANPEP | NEUTRAL ZINC METALLOPEPTIDASE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 348353628 | | |
290 | ANPEP | NEUTRAL ZINC METALLOPEPTIDASE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, PROTEASE, ENZYME | | CEPHALOSPORINS | | 8774083 |
290 | ANPEP | NEUTRAL ZINC METALLOPEPTIDASE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, PROTEASE, ENZYME | | CEFADROXIL | CEFADROXIL | 8774083 |
290 | ANPEP | NEUTRAL ZINC METALLOPEPTIDASE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 315661176 | | |
290 | ANPEP | NEUTRAL ZINC METALLOPEPTIDASE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, PROTEASE, ENZYME | | ZINC SULFATE | | 14568236 |
290 | ANPEP | NEUTRAL ZINC METALLOPEPTIDASE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 348353627 | | |
290 | ANPEP | NEUTRAL ZINC METALLOPEPTIDASE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 252166766 | | |
290 | ANPEP | NEUTRAL ZINC METALLOPEPTIDASE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME, PROTEASE, ENZYME | | TRANSFORMING GROWTH FACTOR | | 15138629 |